

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**EGM**”) of the Sinopharm Tech Holdings Limited (the “**Company**”) will be held at Units 01–03, 25/F, Corporation Park, 11 On Lai Street, Shatin, New Territories, Hong Kong on Monday, 11 October 2021 at 11:00 a.m., for the purpose of considering and, if thought fit, passing the following resolution:

ORDINARY RESOLUTIONS

1. “**THAT**

- (a) the loan capitalisation agreement dated 8 June 2021 entered into between the Company (as issuer) and Mr. CHAN Ting (as subscriber) (the “**First Loan Capitalisation Agreement**”) in relation to the allotment and issue of 23,076,923 new ordinary shares (“**Mr. CHAN Subscription Shares**”) in the share capital of the Company at a subscription price of HKD0.26 per share, credited as fully paid and which shall rank *pari passu* in all respects with the ordinary shares then in issue, by the Company to Mr. CHAN Ting and the transactions contemplated thereunder (including the allotment and issue of Mr. CHAN Subscription Shares), be and are hereby approved, confirmed and ratified; and

- (b) any one or more directors of the Company (the “**Directors**”) be and is/are hereby authorised generally to take all necessary steps and do all such acts and things and to sign and execute all documents (including the affixation of the common seal of the Company where execution under seal is required) which he/she/they may consider necessary, appropriate, desirable or expedient for the purpose of or in connection with, the implementation of and giving effect to the First Loan Capitalisation Agreement and the allotment and issue of Mr. CHAN Subscription Shares and all other matters incidental thereto or in connection therewith, and to agree to and make such variations, amendments or waivers of any of the matters relating thereto or in connection therewith.”

2. “**THAT**

- (a) the loan capitalisation agreement dated 8 June 2021 entered into between the Company (as issuer) and Madam CHEUNG Kwai Lan (“**Madam CHEUNG**”) (as subscriber) (the “**Second Loan Capitalisation Agreement**”) in relation to the allotment and issue of 89,166,585 new ordinary shares (“**Madam CHEUNG Subscription Shares**”) in the share capital of the Company at a subscription price of HKD0.26 per share, credited as fully paid and which shall rank *pari passu* in all respects with the ordinary shares then in issue, by the Company to Madam CHEUNG and the transactions contemplated thereunder (including the allotment and issue of Madam CHEUNG Subscription Shares), be and are hereby approved, confirmed and ratified; and
- (b) any one or more Directors be and is/are hereby authorised generally to take all necessary steps and do all such acts and things and to sign and execute all documents (including the affixation of the common seal of the Company where execution under seal is required) which he/she/they may consider necessary, appropriate, desirable or expedient for the purpose of or in connection with, the implementation of and giving effect to the Second Loan Capitalisation Agreement and the allotment and issue of Madam CHEUNG Subscription Shares and all other matters incidental thereto or in connection therewith, and to agree to and make such variations, amendments or waivers of any of the matters relating thereto or in connection therewith.”

3. “**THAT**

- (a) the loan capitalisation agreement dated 8 June 2021 entered into between the Company (as issuer) and Ms. NG Pik Yin (“**Ms. NG**”) (as subscriber) (the “**Third Loan Capitalisation Agreement**”) in relation to the allotment and issue of 21,461,538 new ordinary shares (“**Ms. NG Subscription Shares**”) in the share capital of the Company at a subscription price of HKD0.26 per share, credited as fully paid and which shall rank *pari passu* in all respects with the ordinary shares then in issue, by the Company to Ms. NG and the transactions contemplated thereunder (including the allotment and issue of Ms. NG Subscription Shares), be and are hereby approved, confirmed and ratified; and

- (b) any one or more Directors be and is/are hereby authorised generally to take all necessary steps and do all such acts and things and to sign and execute all documents (including the affixation of the common seal of the Company where execution under seal is required) which he/she/they may consider necessary, appropriate, desirable or expedient for the purpose of or in connection with, the implementation of and giving effect to the Third Loan Capitalisation Agreement and the allotment and issue of Ms. NG Subscription Shares and all other matters incidental thereto or in connection therewith, and to agree to and make such variations, amendments or waivers of any of the matters relating thereto or in connection therewith.”

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 23 September 2021

Registered Office:

Second Floor, Century Yard,
Cricket Square, P.O. Box 902
Grand Cayman KY1-1103
Cayman Islands

*Head office and principal place of
business in Hong Kong:*

Units 01–03, 25/F.
Corporation Park
11 On Lai Street, Shatin
New Territories, Hong Kong

Notes:

1. A shareholder of the Company entitled to attend and vote at the EGM (or at any adjournment thereof) is entitled to appoint another person as his/her/its proxy to attend and vote in his/her/its stead in accordance with the articles of association of the Company. A proxy need not be a shareholder of the Company. A form of proxy for use at the EGM is enclosed.
2. In order to be valid, this form of proxy together with the power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority, must be deposited at the Hong Kong branch share registrar and transfer office of the Company, Tricor Standard Limited at Level 54, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the holding of the EGM or any adjournment thereof. Completion and return of a form of proxy will not preclude a shareholder of the Company from attending in person and voting at the EGM or any adjournment thereof, should he/she/it so wish and in such event, the proxy shall be deemed to be revoked.
3. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of other joint holder(s), and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of such shares.

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.